Staples, Inc. (NASDAQ:SPLS) on Mar. 6 announced that its Board of Directors has declared a quarterly cash dividend on Staples, Inc. common stock of $0.12 per share. The dividend is payable on April 17, 2014, to shareholders of record on March 28, 2014. Staples, Inc. (NASDAQ:SPLS) stock performance was -2.43% in last session and finished…
ISIS Pharmaceuticals Inc (NASDAQ:ISIS)’s stock had its “positive” rating restated by stock analysts at BMO Capital Markets in a report issued. ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) stock performance was -6.21% in last session and finished the day at $46.05. Traded volume was 2.88million shares in the last session and the average volume of the stock remained…
Geron Corp. (NASDAQ:GERN)‘s stock had its “positive” rating reaffirmed by equities researchers at Wells Fargo & Co. in a research report issued on Thursday, AnalystRatings.NETreports. Geron Corporation (NASDAQ:GERN) stock performance was 5.62% in last session and finished the day at $1.78. Traded volume was 16,397,352 million shares in the last session and the average volume…
Rite Aid Corporation (NYSE:RAD) on Mar. 10 announced a new program, Rite Aid Health Alliance, a pioneering health management collaboration among various healthcare providers that provides comprehensive care and support to individuals with chronic and poly-chronic health conditions and helps them achieve health improvement goals established by their physicians. Rite Aid Corporation (NYSE:RAD) stock performance…
Yandex NV (NASDAQ:YNDX), Russia’s biggest Internet company, plunged 8.4 percent to $29.16, the lowest level since July. The Market Vectors Russia ETF (RSX) slumped 4.4 percent to $21.05, the lowest since July 2009. Yandex NV (NASDAQ:YNDX) stock performance was -8.42% in last session and finished the day at $29.16. Traded volume was 15.85million shares in…
OXiGENE Inc (NASDAQ:OXGN) on Mar. 11 announced positive results from a randomized Phase 2 clinical trial evaluating Avastin(R) (bevacizumab) with or without ZYBRESTAT(R) (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less…
Tech Analysis & Market News